# Zanubritnib and Anti-MAG Neuropathy

> **NCT07392229** · PHASE2 · RECRUITING · sponsor: **Azienda Ospedaliera di Padova** · enrollment: 50 (estimated)

## Conditions studied

- Anti-MAG IgM-associated Demyelinating Polyneuropathy

## Interventions

- **DRUG:** Zanubrutinib Oral Capsule

## Key facts

- **NCT ID:** NCT07392229
- **Lead sponsor:** Azienda Ospedaliera di Padova
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2031-03
- **Final completion:** 2031-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392229, "Zanubritnib and Anti-MAG Neuropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07392229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*